APA (7th ed.) Citation

Kinoshita, T., Takekita, Y., Hiraoka, S., Tamura, F., & Iwama, Y. (2023). Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication. Wiley.

Chicago Style (17th ed.) Citation

Kinoshita, Toshihiko, Yoshiteru Takekita, Shuichi Hiraoka, Fumihiro Tamura, and Yasuhiro Iwama. Long‐term Safety and Efficacy of Sublingual Asenapine for the Treatment of Schizophrenia: A Phase III Extension Study with Follow‐up for 52 weeks (P06125)—Secondary Publication. Wiley, 2023.

MLA (9th ed.) Citation

Kinoshita, Toshihiko, et al. Long‐term Safety and Efficacy of Sublingual Asenapine for the Treatment of Schizophrenia: A Phase III Extension Study with Follow‐up for 52 weeks (P06125)—Secondary Publication. Wiley, 2023.